Busan BGSS Eye Clinic · JCI-Accredited Ophthalmology Since 1997 · 7-Language Patient Care
JCI-Accredited · Since 1997
en-US
Presbyopia Correction · Needs Clinic Confirmation
Presbyopia ICL Viva
EVO Viva ICL is a phakic intraocular lens procedure that corrects both myopia and presbyopia simultaneously — without removing the natural crystalline lens, without corneal ablation, and without the monovision compromise of correcting each
Schedule a ConsultationWhat Is EVO Viva ICL? Presbyopia and Myopia Correction Without Lens Removal in Busan

EVO Viva ICL is a phakic intraocular lens procedure that corrects both myopia and presbyopia simultaneously — without removing the natural crystalline lens, without corneal ablation, and without the monovision compromise of correcting each eye differently. A soft EVO Viva lens made from biocompatible Collamer material is implanted in the posterior chamber between the iris and the natural crystalline lens, adding the optical correction needed to restore clear vision at near, intermediate, and far distances in both eyes together.
This positions EVO Viva ICL as a fundamentally different presbyopia correction option from multifocal IOL surgery, which requires removal of the natural crystalline lens, and from laser monovision approaches, which sacrifice one eye's distance vision to improve near vision in the other. At Busan BGSS Eye Clinic in Seomyeon, Busanjin-gu, EVO Viva ICL preserves the eye's natural structure entirely — the crystalline lens remains in place, the iris is undamaged, and the cornea is untouched — while delivering full-distance vision correction in both eyes simultaneously.
The BGSS network's founding director was the first surgeon in Korea to perform EVO Viva ICL in 2023, following a presbyopia surgery history that began with the co-performance of the first presbyopia procedure alongside Dr. Schachar — the US founder of SRP presbyopia surgery — during his team's visit to BGSS in 2000. Clinical results from the Seomyeon, Busanjin-gu clinic's Viva ICL program were presented consecutively at the 2025 VIVA ICL User Meeting and the 2025 Korea EVO ICL Forum, establishing the BGSS network as the leading clinical reference for Viva ICL outcomes in Korea.
Who Is a Candidate for EVO Viva ICL in Busan?
EVO Viva ICL at Busan BGSS Eye Clinic in Seomyeon is designed for patients in their 40s and above who want to correct both myopia and presbyopia in a single procedure — without cataract surgery, without losing their natural crystalline lens, and without the visual compromises of monovision. Our team at the Busanjin-gu, Busan clinic evaluates each patient's ocular health, anterior chamber dimensions, refractive prescription, and lifestyle before recommending EVO Viva ICL or an alternative pathway.
Ideal candidates include:
Adults in their 40s and 50s experiencing myopia alongside progressive near vision loss who want clear vision at all distances without reading glasses or bifocals at the Seomyeon facility
Those wanting presbyopia correction without cataract surgery — EVO Viva ICL corrects presbyopia while preserving the natural crystalline lens, making cataract surgery an option later if needed rather than a requirement now
Patients with thin corneas, high myopia, or extreme myopia — EVO Viva ICL does not ablate the cornea, making it accessible to patients excluded from laser-based presbyopia correction at the Busan facility
Those with a history of LASIK or LASEK — EVO Viva ICL is compatible with previously treated corneas and can provide additional refractive and presbyopic correction on top of earlier laser surgery at the Seomyeon, Busanjin-gu clinic
Patients wanting natural far, intermediate, and near vision in both eyes — unlike monovision, EVO Viva ICL corrects both eyes for all distances, preserving binocular depth perception and visual balance
Those concerned about dry eye — corneal preservation means post-operative dry eye and halos are minimized compared with laser presbyopia approaches at the Busanjin-gu, Busan facility
International patients traveling to Busan in their 40s–50s who need a clearly defined, efficient surgical pathway with multilingual coordination and post-operative management
Patients with active cataract progression, insufficient anterior chamber depth, unstable refraction, or active ocular disease are evaluated for alternative pathways. Patients in their 60s with existing cataract are typically directed toward laser multifocal cataract surgery at the Seomyeon clinic.
Our Team at Busan BGSS Eye Clinic, Seomyeon
EVO Viva ICL at Busan BGSS Eye Clinic is performed and managed by our team of five senior directors, each holding concurrent academic appointments at major regional universities in Busan. The BGSS network's presbyopia and ICL surgical history — spanning the first Korean presbyopia surgery in 2000, ICL introduction in 2002, V-Toric ICL development in 2020, and Korea's first Viva ICL in 2023 — represents one of the most comprehensive lens implantation clinical trajectories in the country, and forms the foundation of the Viva ICL program at the Seomyeon, Busanjin-gu clinic.
Our team applies a proprietary Viva ICL surgical strategy developed through 66,000+ ICL clinical cases, including precise lens sizing calibrated to Asian ocular anatomy, same-day bilateral surgery capability, and a Mix & Match approach combining standard ICL and Viva ICL where individual clinical presentations require it. Clinical results from this program — presented at two consecutive international forums in 2025 — demonstrate a 0.99 correlation coefficient between target and achieved vision, confirming the predictability and reproducibility of the Viva ICL approach at the Busanjin-gu, Busan facility.
EVO Viva ICL Advantages: Why It Changes Presbyopia Correction for the 40s–50s
EVO Viva ICL at Busan BGSS Eye Clinic offers a combination of advantages unavailable in any single alternative presbyopia correction approach:
Simultaneous myopia and presbyopia correction — both refractive errors addressed in one procedure at the Seomyeon clinic, without cataract surgery
Natural crystalline lens preserved — no irreversible lens removal; future cataract surgery remains possible if needed at the Busan facility
Cornea untouched — eligible for thin corneas, high myopia, extreme myopia, and post-LASIK patients at the Busanjin-gu, Busan clinic
Both eyes corrected for all distances — no monovision compromise; binocular depth perception maintained at the Seomyeon facility
UV-blocking Collamer lens — built-in UV-A and UV-B protection reduces cataract and macular degeneration risk
Reversible — lens removable if clinical circumstances require it at the Busan BGSS clinic
Dry eye and halos minimized — corneal nerve preservation prevents the post-operative dry eye associated with laser presbyopia approaches
Post-operative management system — systematic follow-up and linked warranty program at the Seomyeon, Busanjin-gu facility
EVO Viva ICL Procedure Steps and Recovery Timeline

EVO Viva ICL at Busan BGSS Eye Clinic in Seomyeon, Busanjin-gu is performed under topical anaesthetic drops. The full pathway:
Pre-Operative Assessment and Viva ICL Planning — Our team conducts anterior chamber depth measurement, corneal topography, refraction, presbyopic range assessment, endothelial cell count, and lifestyle evaluation at the Seomyeon clinic. These data points determine Viva ICL lens power, size, and surgical strategy — including whether a standard ICL/Viva ICL Mix & Match approach is appropriate for each patient at the Busanjin-gu, Busan facility.
Same-Day Bilateral Surgery — Both eyes are treated in a single surgical session at the Seomyeon, Busanjin-gu clinic using the BGSS same-day bilateral protocol — minimizing total visits and recovery time for patients traveling to Busan from abroad. Pre-operative lens discontinuation requirements: soft lenses 1 week; hard lenses and toric soft lenses 2 weeks; orthokeratology lenses 4+ weeks.
EVO Viva ICL Implantation — The Viva ICL is inserted through a small self-sealing corneal incision and positioned in the posterior chamber between the iris and the natural crystalline lens at the Seomyeon facility. No corneal ablation, no lens removal, and no iridotomy occur at any stage. The natural crystalline lens and iris remain entirely intact throughout the procedure.
Lens Position and Vision Confirmation — Following implantation, our team at the Busanjin-gu, Busan clinic confirms lens centration, vaulting, intraocular pressure, and preliminary visual function before discharge. Prescribed anti-inflammatory and antibiotic drops and post-operative instructions are provided.
Follow-Up and Vision Stabilization — A next-day review at the Seomyeon, Busanjin-gu clinic assesses uncorrected visual acuity across all distances, lens position, and IOP. BGSS clinical data shows 83% of Viva ICL patients achieve uncorrected vision of 0.8 or better at one month, with 98% reaching best corrected vision of 0.8 or better at three months.
Post-Operative Management Program — Our team operates a systematic long-term follow-up program at the Seomyeon clinic, monitoring lens stability, IOP, endothelial cell health, and age-related ocular changes — with the linked warranty program providing formal outcome assurance for every Viva ICL patient at the Busanjin-gu, Busan facility.
EVO Viva ICL Results, Safety, and Longevity
BGSS network clinical data from EVO Viva ICL patients (November 2023 – March 2025) demonstrates a correlation coefficient of 0.99 between target and achieved vision — a 99% target vision achievement rate confirming the predictability of the Viva ICL approach at the Seomyeon, Busanjin-gu clinic. At one month post-operatively, 83% of patients achieved uncorrected vision of 0.8 or better; at three months, 98% achieved best corrected vision of 0.8 or better; and more than 9 in 10 patients were able to manage daily life without glasses at the three-month mark. Results vary by individual and no specific outcome is guaranteed.
EVO Viva ICL's safety profile is grounded in 20+ years of global ICL clinical experience across more than 2,000,000 procedures worldwide, with the Collamer lens material's biocompatibility extensively validated. At the Busanjin-gu, Busan clinic, the cornea-preserving design eliminates laser-related dry eye and corneal thinning risks, the UV-blocking lens provides ongoing cataract and macular degeneration protection, and the reversible implant design provides a clinical safety layer. Potential side effects include temporary halos, mild light sensitivity, and an adaptation period for presbyopic range — generally resolving as visual adaptation progresses. Serious complications are uncommon and our team's pre-operative assessment and structured monitoring at the Seomyeon facility minimizes risk further.
EVO Viva ICL produces stable long-term correction for both myopia and presbyopia. The Collamer lens does not degrade over time, and the preserved natural crystalline lens retains its biological function. Future cataract surgery, if required, remains possible without the Viva ICL being a contraindication. Our team discusses realistic adaptation timelines and long-term expectations with every patient before surgery is planned at the Busan BGSS clinic.
Why Choose Busan BGSS Eye Clinic in Seomyeon for EVO Viva ICL?

Busan BGSS Eye Clinic performed Korea's first EVO Viva ICL in 2023 — and has since presented clinical outcomes at two consecutive international forums, establishing the Seomyeon, Busanjin-gu clinic as the leading Viva ICL reference center in Korea. Our team of five senior directors brings the ICL surgical depth, presbyopia correction history, and Asian ocular anatomy expertise that Viva ICL's precision demands — supported by 66,000+ ICL clinical cases, same-day bilateral surgery capability, and the proprietary Mix & Match strategy for complex presbyopic presentations at the Busanjin-gu, Busan facility. As the founding BGSS location since 1997 with 330,000+ vision correction surgeries, the Seomyeon clinic's credentials are clear:
Korea's first EVO Viva ICL clinic — clinical results presented at 2025 VIVA ICL User Meeting and Korea EVO ICL Forum
99% target vision achievement rate — 0.99 correlation coefficient across BGSS Viva ICL clinical data
First ophthalmology clinic in Korea to receive JCI accreditation — four cycles
Asia-Pacific Regional Center for EVO ICL Training (2026) and Advanced Regenerative Medicine Institution (2026)
Key Medical Tourism Cooperative Institution, City of Busan — multilingual support in Chinese, English, Japanese, Mongolian, Russian, Vietnamese, and Indonesian
Patient Experiences: EVO Viva ICL at Busan BGSS Eye Clinic, Seomyeon
Patient Vignette 1 — Myopia with Presbyopia, Early 50s
A patient in their early 50s traveling to Busan had been managing both distance myopia and progressive near vision loss simultaneously, and was not ready for cataract surgery. Following pre-operative assessment at the Seomyeon, Busanjin-gu clinic confirming adequate anterior chamber depth and stable refraction, our team performed same-day bilateral EVO Viva ICL. At the three-month review, the patient reported clear vision at all distances without glasses in daily life. Results vary; no outcome is guaranteed.
Patient Vignette 2 — Post-LASIK Presbyopia, Late 40s
A patient in their late 40s at the Busanjin-gu, Busan clinic had undergone LASIK over a decade earlier and was experiencing progressive near vision difficulty. Laser-based presbyopia re-treatment was assessed as unsuitable given prior corneal ablation. Our team at the Seomyeon facility recommended EVO Viva ICL as a cornea-independent alternative. Both eyes were treated in a single visit and the patient achieved functional near and far vision without reading glasses at the one-month follow-up. Individual results vary and no specific outcome is guaranteed.
See at Every Distance Without Glasses — Book Your EVO Viva ICL Consultation in Busan
If myopia and presbyopia are affecting your daily life and you want to correct both in a single procedure — without removing your natural lens, without corneal ablation, and without the visual compromise of monovision — our team at Busan BGSS Eye Clinic in Seomyeon, Busanjin-gu is ready to evaluate your suitability for EVO Viva ICL. As Korea's first Viva ICL clinic, with a 99% target vision achievement rate, JCI accreditation, Asia-Pacific EVO ICL Training Center status, and same-day bilateral surgery capability, the Seomyeon clinic offers the presbyopia ICL expertise that patients in their 40s and 50s deserve. International patients are fully supported in Chinese, English, Japanese, Mongolian, Russian, Vietnamese, and Indonesian.
**[Book Your Free EVO Viva ICL Consultation at Busan BGSS Eye Clinic](/contact-us)
Other Services
Explore our comprehensive range of healthcare offerings tailored to your needs.
Dry Eye Diagnostic Testing
It is a spectrum of disorders with distinct underlying mechanisms — each requiring a different clinical response.
Learn More
Aqua IPL / Aqua Lifting
Dry eye syndrome is one of the most common and undertreated conditions in ophthalmology — affecting contact lens wearers, digital screen users, post-surgical patients, and adults over 40 with progressively declining tear film quality.
Learn More
Autologous Serum Eye Drops
Autologous serum eye drops are a specialized therapeutic preparation in which a patient's own blood is processed to extract the serum — which is then formulated as personalized eye drops.
Learn More